+86-571-85081802     info@multin.cn
High purity of Pomalidomide Pomalyst CAS 19171-19-8 with best price
Home » Products » Pharmaceutical » High purity of Pomalidomide Pomalyst CAS 19171-19-8 with best price

Contact Us

 Tel: +86-571-85081802
  Phone: +86-13655719091
 E-mail: info@multin.cn
  Add: Room 321,lingjun Mansion South,the 10th Chaowang Road,xiacheng District,hangzhou City,zhejiang Province China

High purity of Pomalidomide Pomalyst CAS 19171-19-8 with best price

Share to:

High purity of Pomalidomide Pomalyst CAS 19171-19-8 with best price
Product name :Pomalidomide
CAS NO. 19171-19-8
Synonyms
Pomalidomide

Category Pharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals.
Purity 99% Pomalidomide
Appearance Pomalidomide powder
Shelf life 2 years

  • CAS 19171-19-8
  • MT
  • 19171-19-8
  • 19171-19-8

    High purity of Pomalidomide Pomalyst CAS 19171-19-8 with best price 

 Product Name  pomalidomide
 Appearance  White Fine Powder
 CAS  19171-19-8
 Other Name  Pomalyst
 Grade  Medicine & feed
 Standard  NLT 98%
 Assay  99%min
 Shelf life  2 Years
 Application  cure osteocarcinoma
 Color  White 

  Pomalidomide                                                 

 



111

  Function

Pomalidomide is anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved in February 2013 by the U.S. Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma.


 Our services

1. Supply top quality products with a reasonable price.

2. Arrange the orders and shipping with your requests on time, According to the different countries export policy provide complete customs clearance documents.

3. Samples can be arranged for testing and Unconditional assume responds.

4. Provide a price trend, ensure the clients can know about  marketing informations in time.


Perampanel is a selective noncompetitive antagonist of AMPA receptors, the major subtype of ionotropic glutamate receptors. Perampanel was found to be effective in the treatment of refractory partial-onset seizures in three pivotal (Phase 3) clinical trials and has been approved for marketing under the brand name Fycompa by the European Medicines Agency. The drug is currently approved, for the control of partial-onset seizures, in those of both sexes who suffer from epilepsy and who are 12 years of age and older. Perampanel is discontinued.

Packing and Shipping:


packing

packing1


OUR PRODUCTS

HOT LINKS

Copyright  2020 ZHEJIANG MULTINPHARMA CO.,LTD All Rights Reserved  浙ICP备17013806号-1  |  Technology by www.leadong.com